Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2000 2
2002 4
2003 8
2004 5
2005 4
2006 7
2007 5
2008 7
2009 7
2010 13
2011 4
2012 9
2013 8
2014 7
2015 5
2016 9
2017 6
2018 11
2019 7
2020 2
2021 5
2022 11
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

139 results

Results by year

Filters applied: . Clear all
Page 1
Targeting S100A9 protein affects mTOR-ER stress signaling and increases venetoclax sensitivity in Acute Myeloid Leukemia.
Fan R, Satilmis H, Vandewalle N, Verheye E, De Bruyne E, Menu E, De Beule N, De Becker A, Ates G, Massie A, Kerre T, Törngren M, Eriksson H, Vanderkerken K, Breckpot K, Maes K, De Veirman K. Fan R, et al. Among authors: vanderkerken k. Blood Cancer J. 2023 Dec 18;13(1):188. doi: 10.1038/s41408-023-00962-z. Blood Cancer J. 2023. PMID: 38110349 Free PMC article.
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma.
Emde-Rajaratnam M, Beck S, Benes V, Salwender H, Bertsch U, Scheid C, Hänel M, Weisel K, Hielscher T, Raab MS, Goldschmidt H, Jauch A, Maes K, De Bruyne E, Menu E, De Veirman K, Moreaux J, Vanderkerken K, Seckinger A, Hose D. Emde-Rajaratnam M, et al. Among authors: vanderkerken k. Front Immunol. 2023 Nov 15;14:1286700. doi: 10.3389/fimmu.2023.1286700. eCollection 2023. Front Immunol. 2023. PMID: 38035078 Free PMC article.
Targeting stromal cell sialylation reverses T cell-mediated immunosuppression in the tumor microenvironment.
Egan H, Treacy O, Lynch K, Leonard NA, O'Malley G, Reidy E, O'Neill A, Corry SM, De Veirman K, Vanderkerken K, Egan LJ, Ritter T, Hogan AM, Redmond K, Peng L, Che J, Gatlin W, Jayaraman P, Sheehan M, Canney A, Hynes SO, Kerr EM, Dunne PD, O'Dwyer ME, Ryan AE. Egan H, et al. Among authors: vanderkerken k. Cell Rep. 2023 May 30;42(5):112475. doi: 10.1016/j.celrep.2023.112475. Epub 2023 May 10. Cell Rep. 2023. PMID: 37167967 Free article.
Tasquinimod suppresses tumor cell growth and bone resorption by targeting immunosuppressive myeloid cells and inhibiting c-MYC expression in multiple myeloma.
Fan R, Satilmis H, Vandewalle N, Verheye E, Vlummens P, Maes A, Muylaert C, De Bruyne E, Menu E, Evans H, Chantry A, De Beule N, Hose D, Törngren M, Eriksson H, Vanderkerken K, Maes K, Breckpot K, De Veirman K. Fan R, et al. Among authors: vanderkerken k. J Immunother Cancer. 2023 Jan;11(1):e005319. doi: 10.1136/jitc-2022-005319. J Immunother Cancer. 2023. PMID: 36650020 Free PMC article.
Targeting the β2 -adrenergic receptor increases chemosensitivity in multiple myeloma by induction of apoptosis and modulating cancer cell metabolism.
Satilmis H, Verheye E, Vlummens P, Oudaert I, Vandewalle N, Fan R, Knight JM, De Beule N, Ates G, Massie A, Moreaux J, Maes A, De Bruyne E, Vanderkerken K, Menu E, Sloan EK, De Veirman K. Satilmis H, et al. Among authors: vanderkerken k. J Pathol. 2023 Jan;259(1):69-80. doi: 10.1002/path.6020. Epub 2022 Nov 22. J Pathol. 2023. PMID: 36245401 Free PMC article.
139 results